MAT 9001

Drug Profile

MAT 9001

Alternative Names: MAT-9001

Latest Information Update: 20 Aug 2015

Price : $50

At a glance

  • Originator Matinas BioPharma
  • Class Antihyperlipidaemics; Omega 3 fatty acids
  • Mechanism of Action Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hypertriglyceridaemia
  • Preclinical Dyslipidaemias

Most Recent Events

  • 20 Aug 2015 MAT 9001 is available for licensing as of 18 Aug 2015. http://www.matinasbiopharma.com
  • 15 Jun 2015 Additional pharmacodynamics data from a phase I trial in hypertriglyceridaemia released by Matinas BioPharma
  • 01 Jun 2015 Pharmacokinetic and pharmacodynamic data from a phase I/II trial in Hypertriglyceridaemia released by Matinas Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top